Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: J Am Med Dir Assoc. 2017 Feb 1;18(2):99–104. doi: 10.1016/j.jamda.2016.11.010

Figure 1.

Figure 1

Advisory Committee on Immunization Practices (ACIP) recommended intervals for sequential use of PCV13 and PPSV23 for immunocompetent adults aged ≥65 years. **For adults aged ≥65 years with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid leaks, or cochlear implants, the recommended interval between PCV13 followed by PPSV23 is ≥8 weeks. For those for who previously received PPSV23 when aged <65 years and for whom an additional dose of PPSV23 is indicated when aged ≥65 years, this subsequent PPSV23 dose should be given ≥1 year after PCV13 and ≥5 years after the most recent dose of PPSV23. Depending on their indications, adults may receive up to 3 doses of PPSV23 during their lifetime (2 doses at age <65 years; 1 dose at age ≥65 years), all of which should be given 5 years apart. These materials were adapted from [29].